You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 10,189,822

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,189,822

Title:	Heterocyclic modulators of lipid synthesis
Abstract:	Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders.
Inventor(s):	Oslob; Johan D. (Menlo Park, CA), McDowell; Robert S. (Menlo Park, CA), Johnson; Russell (Menlo Park, CA), Yang; Hanbiao (Menlo Park, CA), Evanchik; Marc (Menlo Park, CA), Zaharia; Cristiana A. (Menlo Park, CA), Cai; Haiying (Menlo Park, CA), Hu; Lily W. (Menlo Park, CA), Duke; Gregory (Menlo Park, CA), Ohol-Gupta; Yamini (Menlo Park, CA), Heuer; Timothy Sean (Menlo Park, CA), O\'Farrell; Marie (Menlo Park, CA)
Assignee:	3-V Biosciences, Inc. (Menlo Park, CA)
Application Number:	15/558,813
Patent Claims:	1. A method of treating a cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of: ##STR00099## ##STR00100## wherein the cancer is selected from mantle cell lymphoma; chronic myelogenous leukemia; sarcoma; endometrial tumors; non-small cell lung carcinoma; gastric carcinomas; hepatocellular tumors; and head and neck cancer. 2. A method of treating a cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of: (i) a first therapeutic agent, wherein the first therapeutic agent is selected from: ##STR00101## ##STR00102## (ii) a second therapeutic agent; wherein the cancer is selected from mantle cell lymphoma; chronic myelogenous leukemia; sarcoma; endometrial tumors; non-small cell lung carcinoma; gastric carcinomas; hepatocellular tumors; and head and neck cancer. 3. The method of claim 2 wherein the second therapeutic agent is a cancer therapeutic agent selected from paclitaxel, doxorubicin, vincristine, actinomycin D, altretamine, asparaginase, bleomycin, busulphan, cabazitaxel, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, epirubicin, etoposide, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, mitomycin, mitozantrone, oxaliplatin, procarbazine, steroids, streptozocin, taxotere, tamozolomide, thioguanine, thiotepa, tomudex, topotecan, treosulfan, uracil-tegufur, vinblastine, vindesine, nivolumab, pembrolizumab, MPDL3280A, MEDI4736, olaparib, erlotinib, necitumumab, traztuzamab, pertuzamab, lapatinib, crizotinib, cabozantinib, onartuamab, ramucirumab, bevacizumab, enzalutamide, abiraterone, tamoxifen, cobimetinib, vemurafenib, everolimus, Kadyzla, sirolimus, avastin, nexavar, sutent, exemtesane, femora, enzalutamide, bicalutamide, Tafinlar, and Zelboraf. 4. The method of claim 2, wherein the first and second therapeutic agents are administered in the same dosage unit. 5. The method of claim 2, wherein the first and second therapeutic agents are administered in separate dosage units. 6. The method of claim 1 or claim 2, wherein the cancer is mantle cell lymphoma. 7. The method of claim 1 or claim 2, wherein the cancer is chronic myelogenous leukemia. 8. The method of claim 1 or claim 2, wherein the cancer is sarcoma. 9. The method of claim 1 or claim 2, wherein the cancer is an endometrial tumor. 10. The method of claim 1 or claim 2, wherein the cancer is non-small cell lung carcinoma. 11. The method of claim 1 or claim 2, wherein the cancer is a gastric carcinoma. 12. The method of claim 1 or claim 2, wherein the cancer is a hepatocellular tumor. 13. The method of claim 1 or claim 2, wherein the cancer is head and neck cancer.

Details for Patent 10,189,822

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978	⤷ Try a Trial	2035-03-19
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2035-03-19
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477	04/21/2014	⤷ Try a Trial	2035-03-19
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.